Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies
Authors' conclusion
The vast majority of patients with CHD have Lp(a) levels far below what is considered a typical risk-enhancing threshold, suggesting that the attributable risk from Lp(a) is more complex than previously perceived.
Study context
- Population
- Adults hospitalised with coronary heart disease (CHD) in the previous 6 to 24 months, 13 countries across 6 World Health Organization (WHO) regions (INTERASPIRE)
- Participants
- 3,928 adults13 countries
- Outcome
- Lp(a) levels (median, Q1-Q3) and proportions above thresholds
Methodological detailsmultinational, central laboratory measurement
- Multinational
- Central laboratory measurement
Main finding
As reported in the abstract
Lp(a) level
- Median Lp(a), overall (Q1-Q3: 11-89 nmol/L)
- 32 nmol/L
- Lp(a) ≥125 nmol/L, overall
- 17.6%
- Median Lp(a), Africa (highest region)
- 62 nmol/L
- Median Lp(a), Western Pacific (lowest region)
- 22 nmol/L
- Median Lp(a), Portugal vs Poland
- 59 nmol/L vs 19.5 nmol/L
- Median Lp(a), Colombia vs Argentina
- 46 nmol/L vs 32 nmol/L
- Median Lp(a), Malaysia vs Philippines
- 39.5 nmol/L vs 14 nmol/L
Observational data: associations, not effects.
Further findings
Proportion with Lp(a) ≥150, 175 and 200 nmol/L (eligibility for future Lp(a)-lowering therapies)
- Overall (≥150, 175, 200 nmol/L)
- 13.0%, 9.3%, and 6.2%
- Portugal (highest)
- 25.5%, 18.3%, and 11.6%
- Philippines (lowest)
- 4.3%, 2.5%, and 1.3%
Original publication
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies. J Am Coll Cardiol. Published 3 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →